What are your feelings regarding the controls for unilateral pain models such as inflammatory (CFA/Zymosan) or neuropathic (SNI)? Ipsi-Contra controls have the advantage of needing fewer subjects and also using the same mouse as its own control (within-subject), minimizing variability between subjects (potentially). The downside is that unilateral treatments might have contralateral effects, as some studies show. There isn’t consistency in this regard.
What do you think?